Rallybio Corp (RLYB) - Form 8-K Summary
Business Context and Reporting Period
Rallybio Corporation, a Delaware corporation and emerging growth company, filed this Current Report on Form 8-K on January 26, 2026. The filing addresses corporate governance actions taken at a Special Meeting of Stockholders held on the same date.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on capital structure changes and voting results.
Material Changes
- Reverse Stock Split: The Company filed a Certificate of Amendment to effect a 1-for-8 reverse stock split of its common stock.
- Effective Date: The split is scheduled to become effective at 12:01 a.m. Eastern Time on February 6, 2026.
- Trading Details: Post-split trading is expected to commence on February 6, 2026, under CUSIP number 75120L 209.
- Voting Results: Stockholders approved the amendment to the Certificate of Incorporation. Of the 42,243,774 shares outstanding as of the December 30, 2025 record date, 34,983,474 shares were represented at the meeting. Proposal 1 received 34,507,021 votes in favor, 464,514 against, and 11,939 abstentions.
Guidance, Outlook, and Risks
The filing does not provide management commentary on future financial guidance, operational outlook, or specific risk factors beyond the standard disclosure of the stock split mechanics. No unusual items or contingencies were reported in this document.
Key Facts for Investor Verification
- Verify the exact timing of the 1-for-8 reverse stock split effective February 6, 2026.
- Confirm the new CUSIP number (75120L 209) for post-split trading.
- Review the impact of the split on the number of shares held and the adjusted share price.
- Note that the filing does not disclose current cash reserves or burn rate, which are critical for biotech firms.